Project Grant R43AI188988
Award Date
12/20/24
Completion Date
11/30/25
Dollars Obligated
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98121, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 in funding to Cellergy Pharma Inc. to develop a bispecific antibody therapy that can efficiently and specifically eliminate IgE-producing B cells without significant side effects. The goal is to achieve complete and durable suppression of allergic symptoms for severe allergic diseases affecting millions of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Abwiz Bio Inc. a $561,538 Phase I Small Business Technology Transfer (STTR) grant under CFDA 93.855 - Allergy and Infectious Diseases Research. The grant will fund the development of neutralizing antibodies against Machupo virus, a New World arenavirus, using a stabilized-trimer immunogen. The goal is to identify and characterize antibodies that target multiple epitopes on the virus surface glycoprotein, which could lead...
This Project Grant award of $1,000,000 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of Partillion Bioscience Corp's advanced antibody discovery workflows. The funding aims to enhance their specialized hydrogel microparticle technology called "nanovials" to enable ultra high-throughput screening and functional assessment of single B cells and antibody-secreting cells. This is expected...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $300,000 to Emmune Inc., a small business in Cambridge, MA, to conduct pre-clinical IND-enabling studies for their ECD4-IG recombinant protein therapeutic for HIV. The goal is to generate data to support an Investigational New Drug (IND) application to the FDA and enable a Phase 1 clinical trial of this long-acting...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $300,000 Project Grant to Electronic Biosciences, Inc. to develop a novel point-of-care technology for monitoring immunosuppressant drug levels. The key product being developed is a portable, fingerstick-based testing system that can provide convenient and frequent immunosuppressant drug level measurements. This will enable more precise dosing for...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development and high-content screening of a library of over 50,000 bifunctional interferon chimera proteins. The goal is to identify and validate improved cell stimulatory functions of these protein chimeras, which have potential applications for treating conditions like multiple sclerosis. The $807,664 award...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Scribe Biosciences, Inc. a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a high-throughput antibody discovery platform against cell membrane-bound proteins. Scribe Biosciences, a for-profit company specializing in microfluidics and biomedical engineering, will utilize its proprietary Microenvironment on Demand (MOD) technology to assemble over 100,000 single-cell...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, has awarded a $300,156 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Intact Genomics Inc., a minority-owned small business. The funding will support research to identify new antifungal compounds with novel mechanisms of action from filamentous fungi. The key objectives are to demonstrate the use of Aspergillus nidulans as a...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Grant Program (CFDA 93.855), provides $304,629 to Lactiga US Inc. to support the preclinical development of LCTG-001, a human secretory IgA replacement therapy for patients with common variable immune deficiency (CVID). The funding will be used to develop a non-clinical intranasal pharmacokinetic profile and formulation framework for LCTG-001...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant valued at $718,758 to the Texas Biomedical Research Institute under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is focused on evaluating the use of IL-21-IgFc fusion protein as a host-directed immunotherapy to improve immune reconstitution and reduce the risk of latent tuberculosis (TB) reactivation in Mycobacterium tuberculosis (MTB) and simian immunodeficiency virus (SIV)...